## **Core Concept**
Chronic myeloid leukemia (CML) is a type of cancer that affects the white blood cells and tends to progress slowly over time. It is characterized by the presence of a specific genetic abnormality known as the **Philadelphia chromosome**, which results from a reciprocal translocation between chromosomes 9 and 22. This abnormality leads to the formation of the **BCR-ABL1 fusion gene**, which encodes a constitutively active tyrosine kinase that drives the proliferation of leukemic cells.

## **Why the Correct Answer is Right**
The correct answer, **Imatinib**, is a **tyrosine kinase inhibitor (TKI)** that specifically targets the BCR-ABL1 tyrosine kinase. By inhibiting this enzyme, imatinib effectively blocks the proliferation of CML cells and induces apoptosis (cell death). Imatinib was the first drug to specifically target the molecular defect responsible for CML, revolutionizing the treatment of this disease. Its introduction has significantly improved the outcomes for patients with CML, making it the first-line treatment for chronic phase CML.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is blank and does not provide a valid choice for consideration.
- **Option B:** This option is also blank and does not offer a legitimate treatment alternative.
- **Option C:** Similarly, this option is blank and lacks relevance to the treatment of CML.
- **Option D:** This option is blank as well and does not represent a viable treatment option for CML.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that **imatinib** and other TKIs have become the cornerstone of CML treatment, significantly improving patient outcomes. Resistance to TKIs can occur, often due to **T315I mutation** in the BCR-ABL1 gene, which is challenging to treat. Clinical vigilance and monitoring for signs of resistance are crucial in the management of CML.

## **Correct Answer Line**
**Correct Answer: B. Imatinib.**